ecrin-mdr-crcClinical2005Colorectal NeoplasmsNeoplasmsColorectal NeoplasmsNeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2049493United States9SunitinibOxaliplatinColorectal cancer,Advanced solid tumors,Sunitinib (SUTENT),LeucovorinFOLFOXFluorouracilECRIN MDRCompletedfalseStudy Of Sunitinib Plus FOLFOX In Patients With Solid TumorsThis study determined the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with FOLFOX [Leucovorin + Fluorouracil (5-FU) + Oxaliplatin]. Three different dosing regimens with starting doses of sunitinib at 37.5 mg/day (Schedule 2/2, Schedule 4/2, and Continuous Dosing) were tested in patients with advanced solid tumors, including colorectal cancer.2005-09-152049493NCT00599924